Insider Purchases: Inside the Buy

Tag: healthcare tech

Illustration of a hospital patient monitor displaying a rising stock chart while a doctor injects a syringe labeled $11.9M, symbolizing Oscar Health’s turnaround driven by CEO insider buying and tech-driven healthcare innovation.

CEO Bets $11.9M: Is Oscar Health (OSCR) About to Shock the Market? 🚀

Oscar Health (OSCR) is no longer just a flashy disruptor—it’s aiming for profitability. With CEO Mark Bertolini buying $11.9M in stock and revenue projected to hit $19B in 2026, this could be one of the most compelling turnaround plays in healthcare.

Read entire article

Tags: ACA, ACA market, buy or sell OSCR, CEO confidence, CEO purchases, disruptive insurance, featured-insiders, fintech healthcare, FUNanc1al, Funanc1al Investing, growth stocks, health insurance stocks, healthcare tech, HealthInsuranceStocks, hub-insiders, insider buying, InsiderBuying, Investing2026, Mark Bertolini, MarkBertolini, multibagger stocks, Oscar Health, OscarHealth, OSCR, OSCR stock, risks buying OSCR, short squeeze stocks, turnaround stocks, undervalued stocks, why buy OSCR
Digital healthcare check-in kiosks in a modern clinic with a falling stock chart in the background and an investor buying during the dip, symbolizing Phreesia’s market selloff and insider confidence.

Phreesia (PHR): Profitable… Then Crushed — Why Insiders Are Loading Up

Phreesia just hit profitability—and got punished for it. With insiders loading up and institutions fully committed, is this a classic overreaction or a value trap? Let’s decode the dip.

Read entire article

Tags: buy or sell PHR, featured-insiders, Fintech, fintech healthcare, FUNanc1al, FUNanc1al Investing, growth stocks, healthcare SaaS, healthcare tech, HealthcareSaaS, high growth stocks, hub-hedge, hub-insiders, insider buying, InsiderBuying, PHR, PHR stock, Phreesia, risks buying PHR, SaaS investing, small cap stocks, stock ideas, stock market analysis, StockMarket2026, turnaround stocks, undervalued stocks, value investing, ValueInvesting, why buy PHR